AMGEN INC — Director's Dealing 2023

Dec 5, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2023-12-04

Reporting Person: Grygiel Nancy A. (SVP & CCO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-04	Common Stock	S	2096	$273.0323	Disposed	10874	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	98.3725	Indirect

Footnotes

F1: The price reported is an average price. The prices ranged from $273.00 to $273.17 per share. Full information regarding the number of shares purchased at each separate price within the range set forth above is available upon request
by the SEC staff, the issuer or a security holder of the issuer.

F2: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 144 RSUs which will vest on 5/5/2024; 2,780 RSUs which will vest on 7/31/2024; 392 RSUs which will vest in installments of 193 on 4/30/2024 and 199 on 4/30/2025; 649 RSUs which will vest in two installments of 214 each on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3: These shares include 397 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

F4: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.